Journal of thrombosis and haemostasis : JTH · 2025
Endothelial protein C receptor-mediated endogenous and therapeutic transport of activated protein C across the blood-retina barrier protects the retina.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Livnat Tami, Budnik Ivan, Nisgav Yael, Dardik Rima, Avishai Einat, Gonen Sheli Rose, Zahavi Alon, Fernández José A, Golderman Valery, Goldberg Zehavit, Kenet Gili, Griffin John H, Levy-Mendelovich Sarina
Аннотация
BACKGROUND: Activated protein C (APC) is a serine protease known for its anticoagulant, anti-inflammatory, and cytoprotective properties. Although clinical evidence links protein C (PC) deficiency to various retinal pathologies, the physiological role of APC in the retina remains unexplored.
OBJECTIVES: To determine whether PC and APC are synthesized locally in the healthy retina or are transported systemically across the blood-retina barrier (BRB) and to evaluate the contribution of the endothelial protein C receptor (EPCR) to APC transport and the therapeutic potential of APC in the retina following systemic administration.
METHODS: We utilized a unique and viable severe protein C deficiency murine model developed in our laboratory. Reverse transcription polymerase chain reaction, immunostaining, and coagulation-based activity assays were used to determine the presence and distribution of PC, APC, and EPCR in the retina and after APC injection via the tail vein. EPCR blockage was performed using an EPCR-neutralizing antibody. The anti-inflammatory activity of the APC analog, 3K3A-APC, was assessed in a murine model of retinal pathologies.
RESULTS: APC is not synthesized locally in the retina but originates from the systemic circulation, crosses the BRB, and accumulates in the retina. EPCR mediates the translocation of APC across the BRB. Systemically administered 3K3A-APC crosses the BRB and induces cytoprotective and anti-inflammatory effects in the retina comparable with intraocular treatment.
CONCLUSIONS: Our findings establish a fundamental step in investigating the concept of PC as a physiologically relevant, naturally protective protein in the eye. Our results support the feasibility of developing noninvasive, systemic APC-based therapies for retinal diseases.
OBJECTIVES: To determine whether PC and APC are synthesized locally in the healthy retina or are transported systemically across the blood-retina barrier (BRB) and to evaluate the contribution of the endothelial protein C receptor (EPCR) to APC transport and the therapeutic potential of APC in the retina following systemic administration.
METHODS: We utilized a unique and viable severe protein C deficiency murine model developed in our laboratory. Reverse transcription polymerase chain reaction, immunostaining, and coagulation-based activity assays were used to determine the presence and distribution of PC, APC, and EPCR in the retina and after APC injection via the tail vein. EPCR blockage was performed using an EPCR-neutralizing antibody. The anti-inflammatory activity of the APC analog, 3K3A-APC, was assessed in a murine model of retinal pathologies.
RESULTS: APC is not synthesized locally in the retina but originates from the systemic circulation, crosses the BRB, and accumulates in the retina. EPCR mediates the translocation of APC across the BRB. Systemically administered 3K3A-APC crosses the BRB and induces cytoprotective and anti-inflammatory effects in the retina comparable with intraocular treatment.
CONCLUSIONS: Our findings establish a fundamental step in investigating the concept of PC as a physiologically relevant, naturally protective protein in the eye. Our results support the feasibility of developing noninvasive, systemic APC-based therapies for retinal diseases.